Clinical Trial VICCTHN1189


Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab plus Etoposide/Platinum versus Etoposide/Platinum in Subjects with Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)

Principal Investigator(s)

Leora Horn


  • Protocol No. VICCTHN1189
  • Open Date: 12/14/2012
  • Staging: Phase III
  • Age Group: Adults
  • Scope: National
  • Objective: To compare overall survival (OS) of subjects randomized to ipilimumab in addition to platinum and etoposide (Arm A) to that of subjects randomized to placebo in addition to platinum and etoposide (Arm B) in subjects with newly diagnosed extensive stage SCLC.
  • Disease Sites: Lung; Small Cell
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Carboplatin; Cisplatin; Etoposide; Ipilimumab
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01450761
  • Secondary Protocol No: CA184156



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.